ORPHA:438159
STAT3-related early-onset multisystem autoimmune disease
Publications
216,526
Trials
0
Interventional, condition-specific
Researchers
0
Distinct authors in sample
Gene link
ADIPOQ, STAT3
Definitive
Readiness
4/6
Stages with a signal
Clinical definition (Orphanet)
A rare, genetic, lymphoproliferative syndrome characterized by early onset recurrent infections, lymphadenopathy with and variable autoimmune disorders, including hemolytic anemia, thrombocytopenia, neutropenia, enteropathy, type I diabetes, scleroderma, arthritis, atopic dermatitis, and inflammatory lung disease. Patients commonly have . Variable immunologic findings include decreased regulatory T-cells, hypogammaglobulinemia, and reduction in memory B cells.
How rare: <1 / 1 000 000 — fewer than one in a million. In a city the size of Kolkata, that might mean on the order of fifteen people.
Cross-references
Joined from Mondo / Orphanet. MeSH labels may enter searches; UMLS / OMIM / NCIT are stored for reference.
- MONDO:0014414
- OMIM:615952
- UMLS:C4014795
- NCIT:C157123
Research stages
Trial readiness signals
Where this condition sits on an open-data research pipeline — not how close a treatment is, and not medical advice. Empty stages often mean “not in these databases under this Mondo ID,” not “impossible.”
4/6 stages with a signal
No specific-condition interventional trial, but broader-category trials exist — discuss eligibility with a clinician.
- Gene identifiedPresent
Definitive — ADIPOQ, STAT3
- LiteraturePresent
216,526 matched papers (162,019 in last 10 years) Source
- Phenotype characterisedPresent
24 HPO annotations (e.g. Type I diabetes mellitus; Autoimmunity; Abnormality of the dentition) Source
- Animal modelNot found
No Alliance genotype “model of” associations via Monarch for these Mondo IDs
- Orphan designationNot found
No FDA or EMA orphan-drug designation matched this disease via UMLS or preferred name Source
- Interventional trialPartial
None under the specific name; 80 for broader category autoimmune disease
Biology
Genes and phenotypes
Gene–disease validity from GenCC, plus phenotypes and animal models joined from Monarch Initiative via Mondo ID — not a clinical diagnosis aid.
Do we know what causes it?
Yes — we know a specific gene responsible (ADIPOQ, STAT3).
GenCC classification: Definitive.
Phenotypes (Monarch / HPO)
24
Associated phenotypes · MONDO:0014414
- Type I diabetes mellitus
- Autoimmunity
- Abnormality of the dentition
- Recurrent lower respiratory tract infections
- Short stature
Showing 5 of 24 — open Monarch for the full list.
Animal models (Monarch / Alliance)
None returned for this Mondo ID. Empty here is not proof that no model organism work exists under another name or gene.
Monarch fetch 2026-07-29
Therapies
Designations, candidates, and chemicals
FDA OOPD and EMA orphan designations, Open Targets clinical candidates, and CTD chemical associations via MyDisease.info. These never change the interventional-trial headline.
Orphan designation (FDA · EMA)
No designation matched this disease via UMLS or preferred name on the FDA OOPD mirror or EMA orphan register. Absence here is not proof that none exists under another wording.
Open Targets candidates
No drugs or clinical candidates returned for this Mondo ID on Open Targets.
CTD chemicals (MyDisease.info)
No CTD chemical associations returned for this Mondo ID.
Literature
Is anyone studying this?
216,526
216,526 papers — among the better-studied rare conditions, though still a fraction of common-disease literature (breast cancer: over 700,000). Median papers in the last 10 years for a rare disease in this dataset (publications denominator n=3967) is 59.
216,526 papers since the earliest indexed year in this search — median last-10-year count for a rare disease in this dataset is 59 (publications denominator n=3967).
162,019 in the last 10 years · low confidence
Phrase hits: 0 · MeSH hits: 0
Who's working on it?
0
Distinct author names in 0 sampled papers.
Who's working on it?
No author names could be extracted from the sampled publications. Try the Europe PMC query in “How we counted this,” or contact an umbrella rare-disease organisation for researcher referrals.
Clinical research
Is a treatment being tested?
0
interventional trials for this specific condition
No interventional trial testing a treatment matched this specific condition name on ClinicalTrials.gov (observational studies and pan-disease registries are listed separately when present). 80 trials are registered for autoimmune disease, the broader category — shown separately because they may or may not enrol this specific subtype.
Data as of 11 September 2026 · last trial check 11 September 2026
No matched interventional trials. This is true for 77.2% of diseases in the trials denominator (5501 of 7126). Here are the researchers publishing on it.
low confidence · 38.6th percentile (trials denominator)
Recruiting interventional trials
From the matched ClinicalTrials.gov set
No interventional trial testing a treatment was found for this specific condition name on ClinicalTrials.gov.
80 interventional trials matched autoimmune disease, the broader category — listed below. Those studies are not counted in the condition-specific total.
Broader category: autoimmune disease
80
Interventional trials for the parent category, exclusive of NCT IDs already counted above. Eligibility for this subtype is not guaranteed.
Worth raising with a clinician. How we count trials.
Recruiting under the broader category
- NCT07778446·NOT YET RECRUITING·A Study to Test CRT-402 in Refractory Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erythematosus · Systemic Scleroderma · Myositis·Matched via name phrase
- NCT07804004·NOT YET RECRUITING·A Safety and Efficacy Study Evaluating CTX112 in Subjects With Refractory Neurologic Autoimmune Disease
Conditions: Progressive Multiple Sclerosis (PMS) · Neuromyelitis Optica · Myelin Oligodendrocyte Glycoprotein Antibody-associated Disease · Autoimmune Encephalitis·Matched via name phrase
- NCT06792799·RECRUITING·Anti-CD19/BCMA CAR-NK Cells in Patients With B Cell Mediated Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus · Multi-Drug Resistant Nephrotic Syndrome · IgAN - IgA Nephropathy·Matched via name phrase
- NCT06347718·RECRUITING·CAR-T Cells in Systemic B Cell Mediated Autoimmune Disease
Conditions: Systemic Lupus Erythematosus · Systemic Sclerosis · Dermatomyositis · Polymyositis·Matched via name phrase
- NCT06435897·NOT YET RECRUITING·Autoimmune Disease Treatment With Mesenchymal Stem Cells (MSCs) and CAR-T Cells
Conditions: Autoimmune Diseases·Matched via name phrase
- NCT06817889·RECRUITING·Remdesivir for the Treatment of Upper Respiratory Tract Infection Due to RSV in Immunocompromised Individuals
Conditions: Hematopoietic and Lymphatic System Neoplasm · Autoimmune Disease · Respiratory Syncytial Virus Infection·Matched via name phrase
- NCT07507201·RECRUITING·Allogeneic CD19/BCMA CAR-T for B Cell-Related Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus (SLE) · Multi-Drug Resistant Nephrotic Syndrome · IgA Nephropathy (IgAN)·Matched via name phrase
- NCT06557265·RECRUITING·A Phase 1/2 Study of NKX019 in Subjects With Autoimmune Disease (Ntrust-1)
Conditions: Lupus Nephritis · Primary Membranous Nephropathy·Matched via name phrase
- NCT00977977·RECRUITING·Rituximab Plus Cyclosporine in Idiopathic Membranous Nephropathy
Conditions: Nephrotic Syndrome · Proteinuria · Autoimmune Disease · Glomerular Disease·Matched via name phrase
- NCT07305116·RECRUITING·CAR T-cell Therapy Targeting CD19 and BCMA in Patients With B Cell Mediated Autoimmune Disease
Conditions: Autoimmune Diseases · Systemic Lupus Erthematosus (SLE) · Multi-Drug Resistant Nephrotic Syndrome · IgA Nephropathy (IgAN)·Matched via name phrase
- NCT07729995·NOT YET RECRUITING·BAFF CAR-T Cells (LMY-922) for Treatment of Refractory Autoimmune Disease
Conditions: Rheumatoid Arthritis (RA) · Systemic Lupus Erthematosus (SLE) · Dermatomyositis (DM) · Systemic Sclerosis (SSc)·Matched via name phrase
- NCT07193667·RECRUITING·CAR-T in Subjects With Relapsed/Refractory Autoimmune Disease
Conditions: Relapsed/Refractory Autoimmune Diseases·Matched via name phrase
- NCT07549698·RECRUITING·Safety and Preliminary Efficacy of CTX112 in Adult Participants With Relapsed/Refractory Hematologic Autoimmune Disease
Conditions: Warm Autoimmune Hemolytic Anemia (WAIHA) · ITP - Immune Thrombocytopenia · Warm Autoimmune Hemolytic Anemia · Immune Thrombocytopenic Purpura·Matched via name phrase
- NCT07085104·RECRUITING·A Study to Investigate the Safety and Preliminary Efficacy of ALLO-329, an Allogeneic CAR T-cell Therapy, in Adults With Autoimmune Disease
Conditions: Systemic Lupus Erythematosus (With and Without Nephritis) · Idiopathic Inflammatory Myopathy · Systemic Sclerosis·Matched via name phrase
- NCT06308978·RECRUITING·A Phase 1 Study of FT819 in B-cell Mediated Autoimmune Disease
Conditions: Antineutrophilic Cytoplasmic Antibody (ANCA)- Associated Vasculitis (AAV) · Idiopathic Inflammatory Myositis (IIM) · Systemic Sclerosis (SSc) · Systemic Lupus Erythematosus (SLE)·Matched via name phrase
Other registries (secondary)
Broader net from EU CTIS, ISRCTN, and ICTRP when available — deduped against ClinicalTrials.gov IDs already counted above. Dual-model LLM relevance gates what we keep. These rows are not added to the interventional headline.
raw 0 · after dedupe 0 · already on CT.gov 0 · kept 0 · parent 0 · uncertain 0 · dropped 0 · fetched 2026-07-30
Source notes: ictrp: Error: ICTRP public search unavailable (WHO portal is SPA-only; SOAP needs partnership). Tried: https://apps.who.int/tri
No secondary-registry studies passed dual-model relevance for this condition name (after dedupe).
Where to find support
Condition-specific patient organisations, when Orphanet lists them, are on the disease’s Orphanet page. We also link umbrella groups that support undiagnosed and ultra-rare families.
Orphanet entry for STAT3-related early-onset multisystem autoimmune disease — check Associations / patient organisations on that page.
India — NPRD
Last verified 2026-07-26This ORPHAcode is not on our curated NPRD list (direct or Mondo-parent match). That does not decide clinical eligibility; families in India should ask a notified Centre of Excellence about current coverage.
Hand-curated for this project. ORPHAcode mappings are best-effort and may be incomplete or imprecise for umbrella categories. Parent (Mondo) matches mean the policy lists a broader category — confirm eligibility with a Centre of Excellence. Financial entitlements summarised from public policy statements and may change. This is not official government guidance.
How we counted this
Europe PMC query (preferred label + any corrected label + Orphanet and Mondo exact synonyms, stoplisted; unioned with resolved MeSH labels when available). UMLS / OMIM / NCIT cross-references are stored on the overview but are not added to the query string.
("STAT3-related early-onset multisystem autoimmune disease") OR ("ADIPOQ" OR "ADIPOQ syndrome" OR "ADIPOQ-related" OR "STAT3" OR "STAT3 syndrome" OR "STAT3-related")ClinicalTrials.gov query (quoted phrases + MeSH via query.cond, plus recall-expansion terms when used):
"STAT3-related early-onset multisystem autoimmune disease"
Study-type breakdown: 0 interventional · 0 observational · 0 expanded access. Only interventional studies enter the trial headline.
Parent-category trials query:
"autoimmune disease"
Query health: ok — strategies attempted: phrase; with hits: none
Parent literature probe: hereditary disease (MONDO:0003847) — 11220 hits
Run this search on ClinicalTrials.gov
Confidence reasoning
- Preferred label is multi-word and distinctive
- No synonyms dropped by stoplist
- No label/synonym collisions with other diseases in this corpus
- Publication count (216526) is implausibly high for prevalence class "<1 / 1 000 000" — treat as possible over-matching, not a measure of research intensity
Ingested 2026-07-27T16:13:59.944Z
